All Industries

TRUST RELATIONS NAMED A FINALIST FOR WOMEN-RUN WORKPLACE OF THE YEAR IN THE 2024 STEVIE® AWARDS FOR WOMEN IN BUSINESS

Trust Relations

Trust Relations has been named a finalist in the 21st annual Stevie Awards for Women in Business for the third consecutive year. The agency was nominated in the category of “Women-Run Workplace of the Year - More than 10 Employees” for cultivating both a considerate company culture and outstanding performance during the 2024 award cycle. Hailed as the world’s premier business awards, The Stevie Awards for Women in Business honor the world’s leading women executives, entrepreneurs, employees and the companies they run. “Trust Relations was born from my desire to create the workplace that I’d always wished existed. It’s so rewarding to not only see that dream come true, but also to be recognized for the considerate culture we have successfully created,” said Trust Relations CEO & Founder April White. “There are so many amazing women in leadership roles now at Trust Relations, who all strive to make this agency the most respectful and collaborative place I have ever worked.” White previously won a Silver Award in the category of “Maverick of the Year” in 2023 and a Gold Award for “Most Innovative Woman of the Year” in 2022, each in the Advertising, Marketing & Public Relations subcategory. White’s previous awards have exemplified her longstanding efforts to improve agency culture and operations, and the communications industry at large, as well as her mission to replace public relations with “trust relations.” This year’s award recognizes the impact a trust-focused approach can have within the workplace, with Trust Relations’ exceptional focus on cultivating a “Considerate Culture” by emphasizing work-life balance, employee wellness, mentorship, and career excellence. Entries were evaluated from the average scores provided by six juries, composed of more than 200 business professionals around the world. Final announcement of Gold, Silver, and Bronze Stevie Award placements will be revealed at the 21st annual awards dinner and presentations. The gala will be held in New York on November 8, 2024. “I couldn’t be more proud of what the women leaders at Trust Relations have accomplished, and their continuous dedication to showing the world what a culture that puts people first can look like,” White said. “The honor of this prestigious award is just one example of what we can achieve together, with our shared commitment to team spirit, work-life balance, and kindness. We hope it will inspire other companies to take a similar approach, in an effort to create the considerate workplaces of the future.” Details about the Stevie Awards for Women in Business and the list of Finalists in all categories are available at www.StevieAwards.com/Women. For more information about Trust Relations, visit www.trustrelations.agency. About Trust Relations Founded in 2019 by award-winning PR veteran-turned-disruptor and official TEDx speaker April White, Trust Relations is the first fully remote strategic communications and integrated marketing agency. It offers access to the best PR and marketing professionals nationwide across every industry. The agency’s proprietary model provides clients with unparalleled transparency, helps align its storytelling and “story-doing,” and unlocks exceptional value for businesses. It also empowers Trust Relations to scale alongside clients by providing everything from basic support to creative activations that maximize brand exposure. The agency’s mission is to replace public relations with “trust relations” by discovering and championing every brand’s authentic truth. Trust Relations’ unique approach and comprehensive suite of services empowers organizations to achieve alignment between what they want people to think about their brands and how they can “show” as well as “tell” stories that demonstrate those proof points. For more information, visit https://www.trustrelations.agency. About The Stevie Awards Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Middle East & North Africa Stevie Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. A ninth program, the Stevie Awards for Technology Excellence, will debut in 2024. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com. Trust Relations, founded in 2019, is a virtual strategic communications firm that creates nimble and proactive “dream teams” for clients through a national network of the industry’s best and brightest practitioners. "Trust Relations" is a term coined by President and Founder April White to describe a new approach to strategic communications focused on communicating clients' authentic actions, value and goodwill. In technology, trust relationships are an administration and communication link between two domains. In communications, they are a bond of mutual respect between a brand and the people it serves. The firm excels at identifying inspiring ways for clients to show their brand value by identifying supportive proof points and ideating creative activations that demonstrate their unique story and value proposition. For more information, visit https://www.trustrelations.agency/. Contact Details April White +1 323-216-8589 april@trustrelations.agency Company Website https://trustrelations.agency/

September 19, 2024 10:00 AM Eastern Daylight Time

Luftgekühlt 10 celebrates Porsche Turbo Anniversary at Universal Studios Backlot

Luftgekuhlt

As the original Porsche icon, the 911 Turbo has become shorthand for high-performance and cutting edge technology. The cars have graced the bedroom wall of thousands of children around the world who grew up idolizing the signature flared fenders and Whale Tail spoiler. Fifty years later, the 930 model, introduced at the Paris Motor Show on October 3, 1974, not only established the 911 Turbo as a legendary vehicle but inserted its name into the vernacular. In recognition of the importance of the 911 Turbo and to celebrate its birthday, Luftgekühlt 10 will showcase a number of landmark vehicles, including a collection of original and modified examples in true Luft style within the Universal Studios Backlot. And in keeping with Luft tradition, the organizers have secured a number of significant racing examples, such as the 930-based Vasek Polak Racing Porsche 934, which claimed the 1976 Trans-Am Championship. Chassis #0179 will be on display; one of two cars entered that year by the California Porsche dealer. It was driven by George Follmer and Hurley Haywood. Throughout the season, Follmer predominantly raced #0174 until a heavy crash saw him swap to #0179. The 934 dominated the Championship, allowing Follmer to win the title with Haywood in second. The team switched to a 935 for the 1977 season. Luft 10 attendees will be able to enjoy the 911 Turbo exhibits as well as a plethora of significant air-cooled Porsches. We’ll reveal more featured cars in the weeks to come. SUPPORTING EVENTS A full itinerary was recently shared via the Luft newsletter, allowing fans to get their Luft fix in more ways than one. The fun starts on Thursday October 3 with the Luft pre-party at Gunther Werks in Huntington Beach, CA. It runs from 7-11pm and all are welcome. Don’t party all night because you won’t want to miss the Rise & Shine pre-party at Race Service on Venice Blvd in Los Angeles. It takes place on October 4 from 9am-12pm and there will be plenty of coffee available. You can then grab lunch before heading over to the Petersen Automotive Museum on Wilshire Blvd in Los Angeles to celebrate 50 years of the 911 Turbo with fellow enthusiasts. Cocktails and gourmet bites will be served but you’ll need tickets to attend, which are available from the Petersen HERE. The event takes place on Friday October 4 from 6-10pm. Following Luft 10 itself – which takes place on Saturday October 5 at the Universal Studios Backlot in Universal City – enthusiasts can join the Mobil 1 Air-Cooled Caravan on October 6. The rally is celebrating its fourth year with a quintessential Los Angeles rally drive. Registered participants will meet at Hansen Dam Recreation Center at 7am and will end at Porsche Santa Clarita with a Cars & Coffee-style event. Registration info will follow shortly. Porsche Santa Clarita is also hosting Porsche owners and enthusiasts at its Official After Luft Brunch on October 6 from 9am-12pm. Anybody wishing to join the event should please register at DOsorio@galpin.com. LUFT 10 TICKETS Although it’s only been a matter of weeks since tickets went on sale, the Early Access option has already sold out. Vehicle registration also closed once the show car capacity was reached. Fortunately, General Admission tickets are still available (at the time of writing) from luftgekuhlt.com/pages/luft-10. However, we’re duty-bound to remind enthusiasts that the last time we visited the Universal Studios Backlot for Luft 6, tickets sold out quickly and many people were disappointed. Don’t be that person who has to experience the event vicariously through other people’s Instagram accounts! SPONSORS Porsche Classic returns, staged in the iconic Gas Station at Universal Studios – the same location it occupied at Luft 6. The Porsche Classic team will globally launch ORIGINALE 10 to celebrate the tenth anniversary of Luft, along with a photo booth to commemorate your visit. Stop by to receive an exclusive wax-sealed event copy of ORIGINALE. Meguiar’s will be located next door in the Engine Company No. 2 Firehouse. The company will have its latest car care products on display, as well as some emergency supplies for owners of exhibition vehicles who forgot to bring detailer! Meguiar’s specialists will be on-hand to answer questions about the correct products to maintain, protect and restore every finish and material on your car to Reflect Your Passion. There will also be a curated display of modified 911 models for visitors to enjoy. Luftgekühlt is also excited to welcome Kinecta Credit Union to its anniversary event, marking the brand’s first appearance. A Southern California original, Kinecta has branches across Los Angeles, Orange, Ventura and Santa Barbara counties. The company is set to make a memorable debut by showcasing two legendary purple Porsches that are sure to captivate Luft fans. The Kinecta team will be located on New York Street, offering exclusive promotions and exciting merchandise. Keep an eye out for the signature Kinecta purple as they immerse themselves in the vibrant Porsche culture that defines Luftgekühlt. Don’t miss out on this exciting addition to the Luft family! EDITOR’S NOTE Images from Luftgekühlt 6 at Universal Studios Backlot are available here: dropbox.com/scl/fo/0febarq3oac99k05cau6i/AG4Tlv7pzV6i_sjLnv8v86w?rlkey=gn9xw9yjf8gz30jf0nqkm52sf&dl=0 A video is available to download and share here: youtu.be/_OM5NqrC3IQ Porsche 934 photos provided by Linhbergh Nguyen for 000 Magazine. ABOUT LUFTGEKÜHLT In the Porsche vernacular, Luftgekühlt represents all the air-cooled cars in the manufacturer’s history, from the Pre-A 356 through the 993 model line, which ended in 1998. A true Porsche happening, Luftgekühlt is an experiential car culture event centered around a tightly curated list of historically significant or interesting cars, both street and race. There is no set formula for our events, but we're excited by cool venues, fun people, and creative expression, so you can bet those elements will always be included. The team strives to develop wild ideas that celebrate the passion we have for all things air-cooled, including exciting collaborations with likeminded people and brands. For more information, visit luftgekuhlt.com Contact Details Media Contact media@luftgekuhlt.com Company Website https://luftgekuhlt.com/

September 19, 2024 06:28 AM Pacific Daylight Time

Image

The worst metro areas for job destruction in 2024

Profit Duel

Experts at ProfitDuel conducted a comprehensive analysis of job destruction across the United States, focusing on metro areas that have experienced the most significant employment losses, including business closures. Using data from the U.S. Census Bureau, they identified the regions most impacted by job destruction. 1. New York - Newark - Jersey City New York - Newark - Jersey City has experienced significant job losses, with 1,699,128 jobs destroyed, driven by the high cost of living, the impact of the COVID-19 pandemic, and the shift towards remote work. Many businesses have either downsized or shut down completely, leading to a substantial reduction in employment opportunities. The hospitality, retail, and office sectors have been particularly hard hit, with 52,159 job losses in the food services industry. 2. Los Angeles - Long Beach - Anaheim Los Angeles - Long Beach - Anaheim ranks as the second worst area for job destruction, with 1,072,714 jobs lost. The entertainment and tourism industries, which are vital to the region's economy, faced severe disruptions during the pandemic. The study revealed that there has been 21,801 job destruction in the arts, entertainment, and recreation sector in this metro. Additionally, the high cost of real estate and operational expenses have forced many small and medium-sized businesses to close their doors permanently. 3. Chicago - Naperville - Elgin Chicago - Naperville - Elgin comes in third in terms of job destruction, with 676,970 jobs lost. The decline in manufacturing jobs, with 12,001 jobs lost in this industry alone, coupled with economic challenges faced by the retail and service sectors, has led to significant job losses. The shift to e-commerce has also negatively impacted traditional brick-and-mortar stores in the area. 4. Dallas - Fort Worth - Arlington Dallas - Fort Worth - Arlington has seen considerable job destruction, with 521,722 jobs lost, particularly in the energy sector. The fluctuating oil prices and the transition to renewable energy sources have resulted in layoffs and business closures. The metro area is also dealing with the aftermath of the COVID-19 pandemic, which has affected various industries, including hospitality and retail. 5. Washington- Arlington-Alexandria The Washington - Arlington - Alexandria metro area has not been immune to job destruction, with 487,619 jobs lost. Government budget cuts, the shift to remote work, and the pandemic's impact on local businesses have contributed to employment losses. The hospitality and service industries have been particularly affected, with many establishments closing permanently. 6. Houston - The Woodlands - Sugar Land Houston - The Woodlands - Sugar Land has faced job destruction, with 474,285 jobs lost, primarily due to the volatility in the energy sector. The oil and gas industry's downturn has led to layoffs and company closures. Additionally, the pandemic's impact on the hospitality and retail sectors has exacerbated the job losses in the region. 7. San Francisco - Oakland - Berkeley San Francisco - Oakland - Berkeley has experienced significant job destruction, with 469,641 jobs lost, due to the high cost of living and the tech industry's shift to remote work. Many businesses have relocated to more affordable areas, leading to job losses in the region. The hospitality and retail sectors have also struggled to recover from the pandemic's effects. 8. Philadelphia - Camden Wilmington Philadelphia - Camden - Wilmington has seen notable job destruction, with 457,451 jobs lost, particularly in the manufacturing and service industries. The decline in traditional manufacturing jobs and the pandemic's impact on small businesses have led to significant employment losses. The region is also grappling with the shift to remote work and e-commerce 9. Boston - Cambridge - Newton Boston - Cambridge - Newton ranks among the worst metro areas for job destruction, with 420,746 jobs lost. The high cost of living, the shift to remote work in the tech and education sectors, and the pandemic's impact on local businesses have all contributed to job losses. The hospitality and retail industries have been hit particularly hard. 10. Miami - Fort Lauderdale - Pompano Beach Miami - Fort Lauderdale - Pompano Beach has faced job destruction, with 415,520 jobs lost, primarily due to the downturn in the tourism and hospitality industries. The pandemic severely impacted these sectors, leading to business closures and layoffs. Additionally, the high cost of living and operational expenses have made it difficult for many businesses to survive. Contact Details Profit Duel Mauricio Garcia +1 929-432-8788 support@profitduel.com Company Website https://www.profitduel.com/

September 19, 2024 09:18 AM Eastern Daylight Time

Image

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025

MIRA Pharmaceuticals, Inc.

By Meg Flippin, Benzinga MIRA Pharmaceuticals (NASDAQ: MIRA), the pre-clinical-stage pharmaceutical company focused on transforming the treatment of neuropathic pain and mental health disorders through scientific research and technological advancements, is making progress in its clinical development planning for Ketamir-2, its novel oral ketamine analog. So much so that the company said that, as part of its strategic development plan, it’s prioritizing early demonstration of Ketamir-2’s clinical efficacy. That could come as early as 2025 through innovative phase 1/2 study designs. What’s more, the company said it's on track for Investigational New Drug (IND) filing with the U.S. Food and Drug Administration (FDA) in December 2024. "Our primary goal is to demonstrate efficacy in humans as quickly as possible," says MIRA Pharmaceuticals chairperson and CEO Erez Aminov. "By implementing specific study designs and leveraging our ongoing preclinical research, we aim to gather early evidence of clinical benefits, positioning our treatment as a transformative option for neuropathic pain." To bolster its approach to clinical and regulatory approval, MIRA said it brought on a consultant with expertise in navigating academia and regulatory bodies, including the Federal Drug Administration. The company said this addition demonstrates that it is serious about meeting the highest standards in clinical development and regulatory compliance. Ketamir-2’s Approach To Fighting Neuropathic Pain and Depression Ketamir-2 is an oral ketamine analog designed to be taken as a pill. It is being investigated for the treatment of neuropathic pain, treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDDSI) and PTSD. Unlike traditional ketamine, which requires intravenous administration, posing accessibility and safety challenges, Ketamir-2 could potentially simplify and improve the treatment experience. The company is exploring Ketamir-2's potential efficacy in treating chemotherapy-induced depression, cancer-related neuropathic pain and diabetic neuropathy. These conditions often have limited treatment options and significant patient populations needing effective therapies. Neuropathic pain alone is a big market, poised to reach over $14 billion by 2034, growing at a CAGR of 5.7% from now until then. Driving demand for drugs to relieve pain is an aging population in the U.S. and an increase in chronic diseases. Collaborating To Speed Time To Market To get testing underway, MIRA Pharmaceuticals said it is collaborating with Formulex, a nano-technology-based drug delivery company, to develop ways to deliver Ketamir-2. The two focus on a spray-dry based granulation of Ketamir-2 in capsules for clinical studies, optimizing the formulation for improved oral bioavailability and patient convenience. A deterrent to more people using ketamine to treat mental health issues and chronic pain is the delivery. Traditional ketamine treatment for depression requires a Risk Evaluation and Mitigation Strategy (REMS) protocol due to its potential for abuse and severe side effects. This involves strict regulations, including requiring intravenous administration under medical supervision, making it less accessible and more costly for patients. In contrast, Ketamir-2, as an oral formulation, aims to provide a more convenient and less intimidating treatment option. By reducing the need for medical supervision and hospital visits, MIRA Pharmaceuticals says Ketamir-2 could enhance patient compliance and decrease overall treatment costs. Phase I Trial Kicking Off Soon Through the phase I/II study designs MIRA is focused on demonstrating the clinical activity in treating neuropathic pain and potentially other neurologic conditions. The idea is to gather data that can drive faster decision-making and potentially expedite patient access, the company said. The phase 1 clinical trial is slated to kick off in the first quarter of 2025 and will be used to assess safety, tolerability and pharmacokinetics in humans. MIRA says that lays the groundwork for subsequent efficacy studies. MIRA collaborates with international academic research institutes to refine and enhance its clinical development strategy. “We are excited to move smoothly forward with our IND-enabling pre-clinical studies towards Phase I trials, which are designed to provide critical insights into the safety and pharmacokinetic profile of our candidate,” said Dr. Angel, chief scientific advisor at MIRA Pharmaceuticals. “This trial is a pivotal step in our journey to bring novel treatment options for neuropathic pain to patients, and we are committed to executing it with the highest scientific and regulatory standards.” Featured photo by Towfiqu barbhuiya on Unsplash. MIRA Pharmaceuticals, Inc., is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. We hold exclusive license rights in the U.S., Canada and Mexico for Ketamir-2, a novel, patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling treatment-resistant depression (“TRD”), major depressive disorder with suicidal ideation (MDSI), and potentially post-traumatic stress disorder (“PTSD”). The statements of the Company's management related thereto contains "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2 and MIRA-55. Any forward-looking statements are based on the Company's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in Annual Report on Form 10-K for the year ended December 31, 2023 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Michelle Yanez +1 305-340-8988 Myanez@mirapharma.com Company Website http://www.mirapharmaceuticals.com/

September 19, 2024 09:00 AM Eastern Daylight Time

Image

Frontieras Launches Investment Opportunity in a “Rockefeller Moment for Coal”

Frontieras

Frontieras has officially announced the launch of their Regulation CF investment opportunity. The company is commercializing its patented technology to transform coal into a thermal fuel that burns as clean as natural gas, while extracting valuable by-products like hydrogen, diesel, jet fuel, fertilizer, industrial chemicals, and more. This is a unique opportunity for individual investors to join them in the early stages. The company calls their innovation the “Rockefeller Moment” for coal, comparing it to John D. Rockefeller’s famed breakthrough innovation in oil-refining technology. While coal has traditionally simply been burned to create energy, Frontieras’ FASForm technology reforms coal into a fuel source that burns cleaner and more efficiently than natural gas, while extracting additional byproducts that are highly valued in global commodities markets. Why invest in Frontieras? Market Potential: The global market for energy and chemicals exceeds $2.1 trillion, encompassing sectors like diesel, hydrogen, jet fuel, and more. Expansion Plan: The company is set to build a state-of-the-art facility in Mason County, West Virginia, with an investment of $850 million. This facility will create 200 full-time jobs and 2,000 construction jobs, boosting the local economy. Proven Track Record: With over $7 million raised from investors to date, Frontieras is already demonstrating strong investor confidence. Matt McKean, Co-Founder & CEO of Frontieras, commented, “Our Reg CF offering is an exciting opportunity for investors to participate in a groundbreaking venture set to redefine the entire global coal industry. These opportunities in the energy sector are rare for individual investors –– they’re typically only available to large institutions. We’re thrilled to give the average investor an opportunity to invest in a major innovation in the global energy industry.” Frontieras Investment Opportunity The Reg CF offering is now accepting investments for a limited time. To learn more about investing in Frontieras and to access the offering details, you can visit their website here. About Frontieras Frontieras specializes in clean coal processing technologies. Their patented FASForm technology transforms coal into high-value commodities, providing a sustainable solution to meet global energy demands while generating substantial economic benefits. To learn more about the company, visit their website at www.frontieras.com. Contact Information: Matthew T McKean CEO, Frontieras North America invest@frontieras.com (304) 316-2060 Frontieras specializes in clean coal processing technologies. Their patented FASForm technology transforms coal into high-value commodities, providing a sustainable solution to meet global energy demands while generating substantial economic benefits. To learn more about the company, visit their website at www.frontieras.com. The Reg CF offering is now accepting investments for a limited time. To learn more about investing in Frontieras and to access the offering details, you can visit their website. Contact Details Matthew T McKean invest@frontieras.com Company Website https://invest.frontieras.com/

September 19, 2024 09:00 AM Eastern Daylight Time

New Horizon Aircraft (NASDAQ: HOVR) Poised For Growth With Hybrid Aircraft Technology Amid Small-Cap Strength

Benzinga

By Gerelyn Terzo, Benzinga The future has arrived, thanks to electric Vertical Take-Off and Landing (eVTOL) aircraft. eVTOLs are aircraft that launch vertically, similar to a helicopter, rather than a conventional takeoff. Hybrid-electric eVTOL designs have the potential to enable greater speed, range and cargo capacity than fully electric versions and could play an important role in the future of aviation. While eVTOL is still in its early days, with the industry currently in the testing phase, its value is predicted to surpass $30 billion by the next decade amid a CAGR of 15.3% since last year. And while Tesla (NASDAQ: TSLA) is playing a key role with electric vehicles, New Horizon Aircraft (NASDAQ: HOVR) hopes to take on a leadership position in the eVTOL aircraft market segment. Toronto-based New Horizon says it has been an early mover in eVTOL technology with its Cavorite X7 prototype aircraft, a hybrid model built for real-world use cases. Its aircraft takes off vertically, true to eVTOL form. However, once in flight, it reverts to the configuration of a conventional airplane, owing to the company’s patented HOVR wing system. The Cavorite X7 is built to reach speeds of 250 miles per hour, with a fuel capacity of more than 500 miles, making it appropriate for real-world applications like travel when the time comes. Learn more about New Horizon Aircraft’s technology here. New Horizon Puts Pedal To The Metal On eVTOL Aircraft Led by a team of operators, aviators and aerospace engineers, New Horizon has been going full throttle of late as it prepares to fully transition its large-scale prototype aircraft by the end of this year. Chief among New Horizon’s priorities is advancing the development of its hybrid-powered eVTOL aircraft. The company has been making strides from a technical standpoint while also building out its team internally. Flight test program: Among the technical highlights, New Horizon has published results on its flight test program, which it says are surpassing its expectations. The company has performed hundreds of flight tests and is nearing full transition speed, which it anticipates achieving by year-end. Full-scale aircraft development: New Horizon says it is innovating the proprietary patent technologies that are critical to its unique aircraft, including full-scale propulsion units that are essential to its HOVR wing technology. Cooling system and power tests for its full-scale propulsion units continue to unfold and it says the outcomes are positive so far. Encouraging test results extend to the company’s Cavorite X7’s patented HOVR wing design, which the company says enables safer, more durable performance even in the most forbidding conditions. Digital twin development: New Horizon harnesses a hardware-in-the-loop (HITL) digital twin technology to test its aircraft, supporting the rapid testing of large-scale prototype aircraft like the Cavorite X7. Its hybrid technology is fueled by its HOVR wing technology, allowing the aircraft to fly nearly all of its missions in a formation that closely resembles that of a conventional aircraft. Meanwhile, the company says the hybrid power system delivers greater range, speed and payloads in its class. When the Cavorite X7 reaches commercialization, New Horizon expects it to have the power to disrupt the travel industry with its speed, efficiency and cost savings over traditional aircraft. However, its potential use cases also extend to medical evacuation, critical supply delivery, disaster relief and special military missions. “Our unique, customer-first approach prioritizes building a tough eVTOL aircraft that can operate in bad weather, icing conditions and other challenging operational environments. This strategy is gaining strong traction with operators, driving substantial demand,” said Horizon Aircraft CEO Brandon Robinson. To keep pace with this ongoing innovation, New Horizon recently expanded its team with the addition of seasoned engineer Tom Brassington as Chief Technology Officer. New Horizon Says It Could Be Poised To Benefit From Possible Small-Cap Stock Demand Earlier this year, New Horizon made its debut in the publicly traded markets amid a business combination with special purpose acquisition company (SPAC) Pono Capital Three. Most recently, New Horizon returned to the equity capital markets with a $2.9 million public offering. The deal, the closing for which was announced in August, comprised 2.8 million Class A ordinary shares with various types of warrants. New Horizon’s timing is no coincidence, as the company says it could be poised to benefit from an expected ongoing rotation in the equity markets into small cap stocks. While small cap stocks have been gaining attention of late, New Horizon took matters into its own hands. It commissioned its own global poll of investment managers to uncover evidence of investor demand for small- and micro-cap names working with more sustainable technologies, where the upside potential is considered greater than larger companies because they are coming from a lower base. The aerospace company says it found that investor demand is in fact there, with more than three-quarters of survey participants demonstrating an expectation for exposure to these asset classes among institutional investors to increase in the next six to twelve months. Slightly more than one-third (34%) of them say allocations to these stocks could increase by at least 25%. Investors who are interested in participating in New Horizon’s growth story can learn more about this company’s financials here. Read more about New Horizon Aircraft: Pilotless Planes Are Coming, But Not Just Yet, Says New Horizon Aircraft CEO On The Horizon: How One Company Plans To Use Its Innovative Aircraft Design To Revolutionize Regional Air Travel From Stage To Stage: How New Horizon Aircraft's eVTOLs Could Simplify Tour Logistics For Taylor Swift Sustainably Featured photo by ELG21 on Pixabay Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2024 08:45 AM Eastern Daylight Time

Image

Brand Engagement Network Brings AI Assistants To Medical Coaching And The $6.7 Billion Concierge Medicine Market Following The Expansion Of Its Board

Benzinga

By Anthony Termini, Benzinga The world of healthcare is rapidly changing, with holistic, accessible care as a key element. In the aftermath of a global pandemic, many patients are demanding a wider range of services that meet a broader range of needs. We may even potentially be entering a golden age of healthcare where patients are being prioritized more than ever, and technology is rapidly advancing to assist physicians in achieving these goals. Brand Engagement Network (BEN) (NASDAQ: BNAI), an artificial intelligence (AI) company, aims to enhance support in this radically expanding industry. The company is an emerging provider of personalized patient engagement. It uses AI to power technology that can see, hear and understand the input it receives from a patient. Using human-like avatars as the interface, BEN says its HIPAA-compliant technology can support highly specific patient requests and can remember, analyze, speak and gesture in a similar way that a person would in a human-to-human interaction. The company’s AI assistants can provide insights about preventative medicine and healthcare options based on a patient’s insurance and health plan while also protecting sensitive medical information. These human-modeled AI assistants are also designed to help augment health and wellness coaching. BEN’s AI Assistants Are Filling Gaps In The Healthcare Industry In August 2024, the company entered an agreement with Members Only Health, a full-service concierge healthcare company. The members-only agreement sets up the development of an AI assistant to serve a number of patient needs. These may include the 24/7/365 availability of a personal concierge to navigate and coordinate the global network Members Only Health (MOH) maintains across providers, health plans and preventative medicine data. Now, MOH expects to have the ability to scale its business much faster and more efficiently by deploying AI assistants to support its growing client base. Nicholas Argento, CEO of Members Only Health says that patients who use healthcare concierge services benefit from professional care around the clock. He adds that AI technology like BEN’s can help ensure that patients “have access to up-to-date healthcare information and the most convenient options for treatment.” The concierge medicine market in the U.S. reached $6.7 billion in 2023. The market is expected to grow annually by nearly 10.4% through 2030. Not to mention, concierge services’ focus on accessibility will be even more important in the coming decades, as our population continues to age; by 2054, 84 million adults ages 65 and older will make up an estimated 23% of the population. BEN also entered into an agreement with INTERVENT International, a key player in the health coaching industry. The agreement with INTERVENT is intended to incorporate human-modeled AI assistants into INTERVENT’s scientifically proven health coaching programs. The goal is to scale a cost-effective, in-depth and conversational support system for both professional health coaches and patient participants. Led by physicians, INTERVENT is a high-tech/high-touch health management company. It delivers evidence-based behavior change and entity-wide or population-based health and wellness coaching. The agreement with BEN is aimed at helping INTERVENT train coaches faster and serve more program participants at a lower cost than would be possible with human interaction alone. INTERVENT’s CEO, Neil Gordon, MD, PhD, MPH, believes AI-driven technology will benefit healthcare providers and patients. He says that “AI will not replace appropriately trained health coaches, but appropriately trained health coaches who leverage purpose-built AI and other technologies are likely to replace those who do not.” How BEN Is Ensuring It Has A Strong Team To Herald In This New Age Of Healthcare And Technology “AI technology offers an incredible opportunity to vastly improve patient outcomes,” said Richard Isaacs, MD, FACS, Dean of the College of Medicine and Professor of otolaryngology at California Northstate University. Isaacs has an intimate understanding of the intersection of technology innovation and medicine and in 2021 was regarded by Modern Healthcare as one of the 100 Most Influential People in Healthcare. Isaacs is a recent addition to BEN’s Board of Directors. At the time of his appointment, he said that he has “always pursued the realization of what is possible in healthcare with new technologies” and that he looks “forward to helping guide BEN’s development of new applications … in the industry.” With the increasing adoption of AI technologies, BEN’s commitment to creating a team of innovators and experts can help set it apart from competitors. Issacs has a long history of embracing new technologies to benefit physicians and patients alike. While he was the chief physician at South Sacramento Medical Center, Issacs led the development and implementation of Kaiser Permanente’s electronic health record system. Under his direction, the facility first began using smartphone applications to help enhance personalized care and improve overall patient experiences. At the company’s core, it is interested in using its proprietary technology to advance industries that require support. It does not seem to be interested in the model of AI for the sake of AI, but rather in developing a robust AI product and connecting with partners to see how it can best assist in bringing evolution to industries in flux. “Improving patient experiences and healthcare outcomes starts with elevating the education and training of healthcare professionals, and enhancing access to healthcare,” said Paul Chang, CEO of BEN. “Supplementing training programs, health coaching (digital and otherwise), and patient engagement with AI technology helps to address significant resource and labor gaps in the healthcare industry while empowering professionals and patients to make informed decisions for optimal health.” Brand Engagement Network believes these agreements will help drive the development of healthcare AI assistants to augment and automate business processes ranging from professional health coaching to patient engagement. The collaborations are expected to help people access specialized healthcare, which may improve patient outcomes. To see more ways BEN is empowering the healthcare industry – as well as other important business sectors worldwide – visit the company’s website. Featured photo by Bermix Studio on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2024 08:35 AM Eastern Daylight Time

Image

The Risks And Rewards Of Betting Big On AI & Big Data

Benzinga

By Kyle Anthony, Benzinga The technological landscape is expanding, with artificial intelligence (AI) starting to play a seminal role in the next generation of computing. Many notable companies are establishing or integrating AI capabilities into their technological infrastructure. The proliferation of AI and its potential to bring about work efficiencies and newfound innovations is raising the expectations not only of consumers but also of investors who have exposure to companies within the AI ecosystem. Chips And Semiconductor Stocks Exceeding Software Stocks While much of the discussion about AI has centered on the Magnificent Seven – Apple (NASDAQ: AAPL), Amazon (NASDAQ: AMZN), Google (NASDAQ: GOOG), Meta (NASDAQ: META), Microsoft (NASDAQ: MSFT), Nvidia (NASDAQ: NVDA) and Tesla (NASDAQ: TSLA) – with a particular focus on Nvidia, the AI ecosystem is expansive and reflects differing stakeholders. Essential to AI development are semiconductors or chips; tiny electronic devices designed to enable functions such as processing, storing, sensing and moving data or signals. AI models employ different types of chips, including memory chips to store large amounts of data and logic chips to process the data. According to Gartner, revenues from AI semiconductors are forecast to be $137 billion by 2027, growing by a five-year compound annual growth rate of 26.5%. As reported by Market Watch, chips/semiconductor stocks outweighed software stocks in the S&P 500 for the first time in June and had the largest overall sector weighting. The changing of the guard reflects Wall Street’s expectations about the semiconductor sector’s ability to capitalize financially on AI. On a company level, Nvidia and Advanced Micro Devices, Inc. (NASDAQ: AMD) are chip designers leading innovation by continuing to push the limits of chip performance, enabling more complex and powerful AI applications. Conversely, end-user companies, such as Meta, are making material investments in their AI capabilities as they continue accelerating infrastructure investments to support their AI roadmap. In Q2 2024, Meta reported total revenues of $36.46 billion and a net income of $12.37 billion, increasing by 27% and 117%; respectively, compared to the same period in 2023. The firm anticipates full-year 2024 capital expenditures will be in the range of $35-40 billion, an increase from their prior range of $30-37 billion, due to their ongoing AI spending. Growing Concerns Of An AI Bubble While AI's potential is significant, growing concerns exist about firms' overinvestment and whether it will manifest as profit or be a cash pitfall. As noted by Forbes, there is a growing sentiment that for the millions that have been invested in AI, the returns thus far have been underwhelming – chatbots lacking a clear monetization strategy, cost-cutting approaches such as AI-driven coding and customer service and AI-powered search that occasionally generates inaccuracies. It would seem that the AI return on investment, thus far, isn’t living up to the large capital expenditures being made. Still, many leading big tech firms remain committed to investing in this space. On the regulatory side, the European Commission recently ratified the European Artificial Intelligence Act (AI Act), the world's first comprehensive regulation on AI. The AI Act aims to ensure that AI developed and used in the European Union (EU) is trustworthy and includes safeguards to protect fundamental rights. The regulation seeks to create a harmonized internal market for AI within the EU, fostering the adoption of this technology and creating a supportive environment for innovation and investment. Given the intense regulatory focus placed on big tech companies, including Alphabet, Amazon, Apple, ByteDance, Meta and Microsoft in Europe, the implications of the AI Act on their operations have yet to be determined. Still, they have the potential to be material in nature. Trading AI And Big Data With Direxion For traders looking to gain leveraged exposure to the fits and starts caused by the volatility of companies involved in the AI ecosystem, Direxion’s Daily AI and Big Data Bull (ARCA: AIBU) and Bear (ARCA: AIBD) 2X Shares offer enhanced, pure-play exposure to companies from the United States that have business operations in artificial intelligence applications and big data. Direxion’s Daily AI and Big Data Bull and Bear 2X Shares seek daily investment results, before fees and expenses, of 200%, or 200% of the opposite, respectively, of the performance of the Solactive US AI & Big Data Index*. They enable short-term traders to gain leveraged exposure to the index’s movements, on either side of the trade. For high-risk traders who are bullish or bearish on AI development, these ETFs present an opportunity to conveniently trade a group of seminal companies and meaningfully participate in their activity. These high-risk ETFs are best suited for those who can actively manage the inherent risks of leverage and are looking to capitalize on short-term trends occurring in the AI and big data industry. Featured photo by Steve Johnson on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. An investor should carefully consider a Fund's investment objective, risks, charges, and expenses before investing. A Fund's prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a Fund's prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fundâs prospectus and summary prospectus should be read carefully before investing. An investor should carefully consider a Fund's investment objective, risks, charges, and expenses before investing. A Fundâs prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain a Fundâs prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. A Fundâs prospectus and summary prospectus should be read carefully before investing. The Index is designed by Solactive AG to represent the securities of companies from the United States that have business operations in the field of artificial intelligence ("AI") applications and big data. Solactive AG is not a sponsor of, or in any way affiliated with, the Direxion Daily AI and Big Data Bull 2X Shares or Direxion Daily AI and Big Data Bear 2X Shares. Direxion Shares Risks - An investment in each Fund involves risk, including the possible loss of principal. Each Fund is non-diversified and includes risks associated with the Fundsâ concentrating their investments in a particular industry, sector, or geographic region which can result in increased volatility. The use of derivatives such as futures contracts and swaps are subject to market risks that may cause their price to fluctuate over time. Risks of each Fund include Effects of Compounding and Market Volatility Risk, Leverage Risk, Market Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Other Investment Companies (including ETFs) Risk, Cash Transaction Risk, Passive Investment and Index Performance Risk, and risks specific to the information technology sector and AI and big data companies. The value of stocks of information technology companies and companies that rely heavily on technology is particularly vulnerable to rapid changes in technology product cycles. Additional risks include, for the Direxion Daily AI and Big Data Bull 2X Shares, Daily Index Correlation Risk and for the Direxion Daily AI and Big Data Bear 2X Shares, Shorting or Inverse Risk and Daily Inverse Index Correlation Risk. Please see the summary and full prospectuses for a more complete description of these and other risks of each Fund. Distributor: ALPS Distributors, Inc. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 19, 2024 08:30 AM Eastern Daylight Time

Image

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

1 ... 57 58 59 60 61 ... 3775

Back